Literature DB >> 15799184

The Coraliance study: non-compliant behavior. Results after a 6-month follow-up of patients on oral contraceptives.

E Aubeny, M Buhler, J C Colau, E Vicaut, M Zadikian, M Childs.   

Abstract

OBJECTIVES: This follow-up study was planned to establish the frequency with which women miss their contraceptive pill, and to observe their behavior when they forget it. In those women who changed from a continuous cycle to an interrupted type of cycle, or vice versa, the study also aimed to evaluate the impact of this change on the pattern of omission of pills.
METHODS: The longitudinal, prospective cohort study included healthy women of child-bearing age for whom a change of pill was being prescribed by their gynecologist. Data were recorded during the 6 months preceding inclusion in the study, and for the 6 months of follow-up; the women were asked to complete a diary in which they recorded the number and exact times of pill omission, and their behavior at each omission.
RESULTS: A total of 617 gynecologists included 3316 women into the study; of these, a group of 2418 (73%) revisited the same gynecologist at follow-up. The groups who either visited the same or a different gynecologist were similar with respect to age, oral contraception type, omission type and frequency. A large non-compliance rate and women's difficulties in maintaining safe contraception after missing a pill were observed in the group with follow-up. Women were never risk-free when they missed a pill; they turned to numerous sources for discordant or conflicting information; 15% of 'not-forgetting' women at the pre-inclusion cycle recorded at least one omission at the last cycle of the 6-month follow-up period. Omission fluctuations during the observational period make it difficult to designate 'forgetful' or 'non-forgetful' classes of women. Administration of the pill in a continuous cycle, and probably 'study' and 'auto-questionnaire' effects, contributed to an improvement in compliance. In the group taking the continuous cycle pill, the omission number slightly decreased, particularly on the first day and week of the cycle, irrespective of the initial cycle type.
CONCLUSIONS: The importance of the phenomenon of non-compliance rate is confirmed as well as women's difficulties in knowing how to maintain contraceptive safety. The continuous cycle regimen is likely to improve women's compliance during the critical period of the cycle.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15799184     DOI: 10.1080/13625180400017776

Source DB:  PubMed          Journal:  Eur J Contracept Reprod Health Care        ISSN: 1362-5187            Impact factor:   1.848


  10 in total

1.  Effect of a low-dose contraceptive patch on efficacy, bleeding pattern, and safety: a 1-year, multicenter, open-label, uncontrolled study.

Authors:  Inka Wiegratz; Susana Bassol; Edith Weisberg; Uwe Mellinger; Martin Merz
Journal:  Reprod Sci       Date:  2014-04-30       Impact factor: 3.060

2.  Pharmacokinetic drug-drug interaction between ethinyl estradiol and gestodene, administered as a transdermal fertility control patch, and two CYP3A4 inhibitors and a CYP3A4 substrate.

Authors:  Julia Winkler; Mark Goldammer; Matthias Ludwig; Beate Rohde; Christian Zurth
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-07-06       Impact factor: 2.441

Review 3.  Continuous or extended cycle vs. cyclic use of combined hormonal contraceptives for contraception.

Authors:  Alison Edelman; Elizabeth Micks; Maria F Gallo; Jeffrey T Jensen; David A Grimes
Journal:  Cochrane Database Syst Rev       Date:  2014-07-29

4.  Pharmacokinetic overview of ethinyl estradiol dose and bioavailability using two transdermal contraceptive systems and a standard combined oral contraceptive.

Authors:  Birte Hofmann; Isabel Reinecke; Barbara Schuett; Martin Merz; Christian Zurth
Journal:  Int J Clin Pharmacol Ther       Date:  2014-12       Impact factor: 1.366

5.  An open-label, two-period comparative study on pharmacokinetics and safety of a combined ethinylestradiol/gestodene transdermal contraceptive patch.

Authors:  Chao Zhang; Haiyan Li; Xin Xiong; Suodi Zhai; Yudong Wei; Shuang Zhang; Yuanyuan Zhang; Lin Xu; Li Liu
Journal:  Drug Des Devel Ther       Date:  2017-03-10       Impact factor: 4.162

6.  Understanding the use of contextual cues: design implications for medication adherence technologies that support remembering.

Authors:  Katarzyna Stawarz; Marcela D Rodríguez; Anna L Cox; Ann Blandford
Journal:  Digit Health       Date:  2016-12-01

7.  Investigation of the hemostatic effect of a transdermal patch containing 0.55 mg ethinyl estradiol and 2.1 mg gestodene compared with a monophasic oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel: an open-label, randomized, crossover study.

Authors:  Wolfgang Junge; Doris Heger-Mahn; Dietmar Trummer; Martin Merz
Journal:  Drugs R D       Date:  2013-09

8.  International survey to assess women's attitudes regarding choice of daily versus nondaily female hormonal contraception.

Authors:  Diana Mansour
Journal:  Int J Womens Health       Date:  2014-04-03

9.  Evaluation of factors associated with noncompliance in users of combined hormonal contraceptive methods: a cross-sectional study: results from the MIA study.

Authors:  Txantón Martínez-Astorquiza-Ortiz de Zarate; Teresa Díaz-Martín; Txantón Martínez-Astorquiza-Corral
Journal:  BMC Womens Health       Date:  2013-10-20       Impact factor: 2.809

10.  Trends in the use of oral contraceptives among adolescents and young women in Spain.

Authors:  Pilar Carrasco-Garrido; Ana López de Andrés; Valentín Hernández-Barrera; Isabel Jiménez-Trujillo; Mercedes Esteban-Peña; Napoleón Pérez-Farinós; Rodrigo Jiménez-García
Journal:  Reprod Health       Date:  2016-09-23       Impact factor: 3.223

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.